Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases.
Kazuyo ShimadaShiori HasegawaSatoshi NakaoRirika MukaiKiyoka MatsumotoMizuki TanakaHiroaki UranishiMayuko MasutaShohei NishidaShinya ShimizuYuichi HayashiAkio SuzukiMitsuhiro NakamuraPublished in: Cancer chemotherapy and pharmacology (2019)
The present analysis demonstrated that the incidence of encephalopathy with ifosfamide should be closely monitored for a short onset (within 7 days). The patients who are administered a high dose of ifosfamide or co-administrated aprepitant should be carefully monitored for the development of encephalopathy.
Keyphrases
- adverse drug
- high dose
- early onset
- end stage renal disease
- drug administration
- drug induced
- electronic health record
- ejection fraction
- newly diagnosed
- emergency department
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- risk factors
- high glucose
- oxidative stress
- endothelial cells
- patient reported
- climate change
- deep learning
- chemotherapy induced